Beloranib
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
Zafgen · Phase 2 · Completed · Enrollment 17
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| ZGN-440 sterile diluent | n/r | n/r | n/r | n/r | n/r |
| 1.2 mg ZGN-440 for injectable suspension | n/r | n/r | n/r | n/r | n/r |
| 1.8 mg ZGN-440 for injectable suspension | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.